POPULARITY
11 episodes with Cancer Institute
4 episodes with Cancer Institute
4 episodes with Cancer Institute
2 episodes with Cancer Institute
5 episodes with Cancer Institute
3 episodes with Cancer Institute
3 episodes with Cancer Institute
3 episodes with Cancer Institute
4 episodes with Cancer Institute
Vivian F. Wu, MD, MPH, is a surgeon-scientist specializing in all cancers of the head and neck, including those of the tongue, throat, voice box, thyroid, skin, and salivary glands. She is the Director of the Head and Neck Cancer Center of Excellence at Saint John's Cancer Institute and Pacific Neuroscience Institute (PNI).Dr. Wu earned her medical degree from Howard University and completed her residency at Oregon Health & Science University. She pursued fellowship training at the University of Michigan. She also holds a Masters in Public Health from Yale University. With over a decade of experience, she provides advanced treatments such as minimally invasive thyroid surgery, transoral robotic surgery, and sentinel node biopsy skin and oral cavity cancers.A believer in multidisciplinary care, Dr. Wu collaborates with experts in oncology, radiation, endocrinology, and dermatology. She is an advocate for HPV vaccination and a former Vice Chair of Research. Dr. Wu is dedicated to improving patient outcomes through innovative care and research, compassionately treating patients at Pacific Head & Neck, Pacific Neuroscience Institute in Southern California.
A powerful rallying cry to protect the world's oceans has been issued from Sir David Attenborough.His message features in a new film, Ocean with David Attenborough, which opens in cinemas across the world today.Plus, Owkin has launched K Navigator, an AI-powered research co-pilot designed to revolutionise biomedical science.They say the technology is an “agentic playground” where researchers can explore, refine, and validate a theory, therefore accelerating the quality and pace of their discoveries.According to the Faculty of Pharmaceutical Medicine, it takes around 12 years for a laboratory discovery to become an approved medicine. There is also a high failure rate.Tech and Science Daily spoke to Dr Ingo Ringshausen, a consultant at University College London Hospital who runs a research group for the Cancer Institute and—importantly—was also one of the first to test the technology.Also in this episode:Could Nasa switch up and launch to Mars as early as 2026?London NHS worker awarded £29,000 after being likened to Darth VaderIs Scotland home to the world's oldest football pitch? Hosted on Acast. See acast.com/privacy for more information.
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here
Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here
Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.
Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.
Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Institute, discusses the continued recruitment of doctors and the strong support of team members as the clinic expands. He highlights progress in clinical and research efforts, along with strategies to support the team amid an influx of patients and the evolving impact of AI in healthcare.
Tune in this time to find out more about NSW's lead cancer control agency - Cancer Insitute NSW. We are joined by Prof Tracey O'Brien, Chief Cancer Officer to talk about her career to date and insights into CINSW's work across the state.
Virology vanguard Dr. Bob Gallo is far from ready to slow down. Now in his seventh decade as one of America's top scientists, he could easily sit back and enjoy the fruits of his numerous and pioneering achievements. His groundbreaking work began in the 1970s with research into human retroviruses, including the discovery of the T-cell growth factor (IL-2) and the identification of the Human T-Cell Lymphotropic Virus (HTLV-1) in 1980, earning him his first Lasker Award, often referred to as “America's Nobel Prize.” His subsequent research led to the identification of HIV-1 as the cause of AIDS, securing him a second Lasker Award. In the 1980s, he was the world's most cited scientist. Along with his team, he developed the first HIV blood test, crucial for understanding the spread of AIDS and managing HIV patients. In the mid 1990's Gallo and his collaborators discovered chemokines, naturally occurring compounds that were essential for understanding how HIV infects cells. Dr. Gallo later founded the Institute of Human Virology at the University of Maryland School of Medicine in 1996 and co-founded the Global Virus Network (GVN) in 2011 to enhance global virus detection and management. Recently, Dr. Gallo and his team moved to Tampa, the new global headquarters for GVN, where he now serves as director of the University of South Florida (USF) Virology Institute and Head of the Microbial Oncogenesis Program at the Cancer Institute at Tampa General Hospital (TGH). In the first part of this wide-ranging interview, Dr. Gallo shares insights into his entry into virology and his initial research into the etiology of certain cancers. This work included crucial discoveries around T cell growth factors, paving the way for identifying HTLV-1. He discusses his collaboration with CDC epidemiologists, which led to recognizing AIDS as being caused by a retrovirus. Once the HIV virus was identified as the cause, creating the first blood test for HIV had profound impacts on the epidemic and patient care. In the second segment, Dr. Gallo discusses the origins of the HIV virus and its early global spread. He also reflects on the COVID-19 pandemic, why the focus on its origins is irrelevant and reflects on how to rebuild public trust in science and medicine, which may have been damaged during the pandemic. In the concluding segment, Dr. Gallo talks about his reasons for joining USF Health and TGH and the research areas he finds most promising going forward. He speculates on the prospects for an HIV vaccine, the impact of artificial intelligence on virology, and why he doesn't necessarily worry about the threat of the next global pandemic. Finally, Dr. Gallo opens up about how the early loss of his young sister deeply affected his life and his desired legacy. Dr Vega would like to thank her friend Job Meiller, her YES Man, for the wonderful musical contributions and coming through on every idea she has. This time he contributes his renditions of Bruce Springsteen's "Streets of Philadelphia" and "Your Song," by Elton John. Thank you Job! Thanks also to Dr. Ana Velez, our artistic contributor, for her painting, "HIV," used in our episode thumbnail.
In this episode, Dr. Boris C. Pasche, President and CEO at Karmanos Cancer Institute, delves into the latest advances in cancer treatment. He highlights exciting developments in theranostics, immunotherapy, and radiofrequency technologies, offering new hope for patients with advanced cancer. Dr. Pasche shares insights on how these therapies are transforming the future of oncology and improving patient outcomes.
For more information about Hamilton Health Care System's imaging services, visit HamiltonHealth.com/imaging. To make an appointment for imaging at Hamilton Diagnostics Center or a mammogram at People's Cancer Institute, call 706-272-6565. To learn more about Peeples Cancer Institute, visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
Para obtener más información sobre los servicios de imágenes de Hamilton Health Care System, visite HamiltonHealth.com/imaging. Para programar una cita para imágenes en Hamilton Diagnostics Center o una mamografía en People's Cancer Institute, llame al 706-272-6565. Para obtener más información sobre Peeples Cancer Institute, visite HamiltonHealth.com/cancer.Este programa de ninguna manera busca diagnosticar o tratar enfermedades ni reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud.
A website for the Prostate Cancer Institute of America: www.prostatecancerusa.comDr, Ajay Bhatnagar: (33) Ajay Bhatnagar MD,MBA | LinkedIn A recent publication from our guest, Dr. Bhatnagar:Modern Low Dose Rate Brachytherapy For Prostate Cancer: A Comprehensive Guide for Urologists: Bhatnagar, Dr. Ajay, Koneru, Dr. Bobby N., Agarwal, Dr. Manuj, Wallner, Dr. Kent, Patel, Dr. Pratik: 9798338512012: Amazon.com: Books
In this episode, Dr. Aaron Spalding, Executive Medical Director at Norton Cancer Institute, discusses innovations in cancer care, the importance of coordinated care teams, and the future of early cancer detection. He also shares insights on leadership in healthcare, emphasizing the value of empathy and listening in both patient care and leadership roles.
In this episode, Laura Matthews, Vice President and Administrator at Inova Schar Cancer Institute, reflects on the institute's five-year milestone. She discusses the institute's rapid growth, the importance of maintaining patient access, and the innovative programs focused on cancer prevention and psychosocial support.
Ann Barshinger passed away at 100 years old, and leaves behind a lasting impact on the people she's served in Central Pennsylvania. Barshinger was known for her big heart and generosity. Over the years, she's donated millions to hospitals, colleges, churches, and many more organizations. Ann was also instrumental in the opening of Ann B. Barshinger Cancer Institute, part of Penn Medicine Lancaster General Health in 2013. Dr. Randall A. Oyer a founding executive medical director of the Ann B. Barshinger Cancer Institute said cancer never touched her family, but wanted to provide support to the families that we impacted by cancer. "People often ask Ann if she had cancer or if someone in her family had had cancer, and she said no. She had simply seen and felt the strain, the stress, the suffering that friends, or others that she knew had to deal with when they, faced the cancer diagnosis and she wanted to make sure that all cancer care was convenient with close to home, that people had better chances of being cured, and that people were treated like human beings, in their cancer treatment, "said Dr. Oyer. Megan Tomsheck is the Senior Vice President and Chief Development Officer with Vision Corps. Tomsheck has known Ann for 10 years says she lived to give, and her legacy will live on for generations to come. " So many times we'd be out having breakfast and somebody would come up and thank her for her support of the Cancer Institute, because they recognized her, because they had a family member who received services. So, it just to watch her little spark go throughout the community. And the ripple effect was was amazing to watch something I'll always be thankful for the opportunity to to be part of, "said Tomsheck. WITF was also a beneficiary of Ann's generosity. She had been a donor for over 20 years, and her foundation supported stipends for interns from York County, among other things. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.
Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite HamiltonHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.
Dr. Shannon Westin and her guest, Dr. Chao Cao, discuss the paper "Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022" recently published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with authors and manuscripts that have been published in the Journal of Clinical Oncology. I'm your host, Shannon Westin, gynecologic oncologist by trade and Social Media Editor for the JCO. And it is my pleasure to welcome Dr. Cao, a research fellow in medicine, Department of Medical Oncology, Dana Farber, Cancer Institute, Boston, Massachusetts. Welcome. Dr. Cao: Thanks for having me. Dr. Shannon Westin: Of course. And we're going to be discussing your very important work, “The Prevalence and Cancer Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022,” which was published in the Journal of Clinical Oncology on April 4, 2024. And Dr. Cao has no conflicts of interest in regards to this podcast. So let's get right into it. I'd love to level set. Can you speak a little bit about the definition of cancer survivorship and the number of cancer survivors currently in the United States? Dr. Cao: I think this is an important question because everyone somewhat has confusion about the definition of cancer survivorship. So based on the definition by the National Cancer Institute, cancer survivorship refers to the phase of life following the diagnosed cancer. And nowadays, it's estimated about 80 million American individuals are living after being diagnosed with cancer. And this number is projected to rise to 26 million by 2040. Dr. Shannon Westin: Wow. So obviously, any research that we can do in this population is going to be so important as that number absolutely continues to grow. And before we get into the specifics of your work, I'd love for you to speak a little bit about the importance of functional disability, which is what we studied in this work and why it might be observed in cancer survivors. Dr. Cao: Yeah, sure. So, maintaining physical function is fundamental to perform life tasks and engage in fruitful jobs. In terms of cancer survivors, many cancer survivors experience side effects from cancer and its treatment. These side effects, include the pain, fatigue, and musculoskeletal dysfunction, which can induce physical limitation and eventually physical disability. And specifically, this is such a burden for the US, social, societal and economic burden. Here I have the specific number: so in 2019, an estimate of over 100,000 people living with and beyond cancer were unable to work and they received a Social Security Administration disability benefit with the resulting cost of US$1.8 billion in disability claims. Dr. Shannon Westin: Wow. We always think about the impact on the survivor, on their family, but I think it's also really important to look at those other objective data about the impact on society as a whole. Thank you, that was great detail. Do we know anything about who might be proportionately more affected by cancer induced physical impairments and disabilities? Dr. Cao: Actually, this is our key question for our manuscript, but before we developed our hypothesis, we also looked at the data from the general population. So we observed that visual minorities and underserved populations, such as people with lower socioeconomic status and living in the rural area, and also those with unhealthy types of behavior, for example, smoking, obesity, and physical inactivity, are more likely to have physical limitations and disabilities. And also the comorbidity in cancer survival, such as diabetes, cardiovascular disease, also increase the likelihood of physical disability. We also have cancer survivors, particularly for cancer patients who are currently receiving cancer treatment, for example, chemotherapy and radiation therapy, they also are more likely to report side effects from the treatment, also have the reduced physical function. So we also think the cancer patients during the treatment also have a higher likely chance to have physical disability. Dr. Shannon Westin: Absolutely. That makes sense, and that really dovetails nicely into the objective of your study. We'd love for you to briefly summarize your objective and the methods you employed to achieve that goal. Dr. Cao: Yeah, sure. We used the six-year data, 2017 to 2022 from the Behavioral Risk Factor Surveillance System to investigate problems and factors of functional disability in over 47,000 cancer survivors and 2.4 million adults without cancer diagnosis aged 80 years and older. And we specifically focused on two types of functional disability. The first one is mobility disability, which is defined as self reported severe difficulty walking or climbing stairs. And also another one is self care disability, which is defined as self reported difficulty dressing or bathing. And also we examined the factors, for example, social demographic characteristics, lapse of behavior, and health related factors, and some cancer related factors, how these factors related to the functional disability. Dr. Shannon Westin: Okay, great. So before we get into your findings, I'd love to hear just a little bit more about the BRFSS, the Behavioral Risk Factor Surveillance System. Why did you choose data from this survey for your study? Dr. Cao: This is a very key question, because nowadays there are no specific cohort studies for cancer survivors. And also actually, in the population based study, there is no field data specifically for the cancer survivor. But fortunately, in the United States, the CDC conducted several nationally representative surveys to examine the health status of the people living in the United States. So we used the data from the Behavioral Risk Factor Survival System, we also called BRFSS. So BRFSS is a nationwide telephone based survey conducted by the CDC and it collects information on health related risk factors and chronic micro conditions among the US adults aged 80 years or older. And specifically for our papers, because recently, the BRFSS also added a section on the cancer survivorship, which included a lot of the variables on cancer, diagnosed cancer type, and also cancer related factor symptoms, for example, the cancer or cancer treatment related pain. So we used this data to realize our idea. Dr. Shannon Westin: Okay, great. So let's start with what you found in regards to the first aspect with mobility disability. Dr. Cao: First, we observed the problems of mobility stability are much higher in cancer survivors than non-cancer adults. And also among cancer survivors, more than 25% of cancer survivors reported mobility disability. We also observe the prevalence of mobility disability is much higher in racial minority groups and underserved populations and those with unhealthy behavior and medical conditions. Dr. Shannon Westin: In addition to the underrepresented minorities, were there any other kind of socioeconomic, demographic factors associated with high prevalence of mobility disability? Dr. Cao: Yes, the factors like lower level of education, income, being unmarried, and living in non metropolitan areas were associated with higher prevalence of mobility disability. And also, I forgot to mention another factor is cancer related factors. We're also including several cancer related factors such as cancer and cancer related pain. So we also observed a higher prevalence of the mobility disability in people, in cancer survivors with cancer and cancer related pain. We also see the prevalence of the mobility disability is much higher in the patients who are currently receiving the cancer treatment than those who already completed the cancer treatment. Dr. Shannon Westin: Yeah, that makes a lot of sense. And to that end, with regards to treatment, were there any cancer specific patterns of mobility disability? Dr. Cao: Yeah, and also, I think this is another strength of our study, because the BRFSS high sample size, which clearly evaluates the mobility disability in over 47,000 cancer survivors, which allowed us to do the cancer specific part of mobility disability. We observed that the survivors of lung cancer and brain cancer and bone cancer have the highest prevalence of mobility disability. And interestingly, we also observed that the women with cancers also had, for example, ovary, cervical cancer survivors also have higher problems of mobility disability. Probably you know, better than me, and I just tell the data. Dr. Shannon Westin: Well, it's interesting, I was thinking, it seems like we have a lot, but I have no, obviously, frame of reference with other cancer types. So it's intriguing to me that that's definitely what we see in our clinic. So I'm intrigued to understand more about this. But before we get into the next steps and that type of thing, I do want to make sure we touch on that other aspect that you looked at, the self care disability and give the listeners a little bit of an idea of what you found there? Dr. Cao: The self care disability is kind of the more severe of the functional disability, which means, we say candidates, lower prevalence compared to the mobility disability, but still the patterns or factors associated with self care disability are much similar with mobility disability. An interesting finding is that in terms of the mobility disability, we find that older survivors are more likely to report mobility disability than younger survivors. In contrast, in terms of the self care disability, younger survivors are more likely to report than the older cancer survivors. Dr. Shannon Westin: You've touched a little bit on some of the socioeconomic and demographic factors that were different with self care disability. Was there anything else that really caught your eye? Cancer specific factors or anything else like that? Dr. Cao: Yeah, besides this, I think also we observe that women are more likely to report self care disability. I think also this is driven by the cancer specific, particularly the woman cancers have a higher prevalence of the self care disability. Dr. Shannon Westin: Well, it's definitely something for me to take back to my clinic. Now that you've covered all these results, how are your data compared to existing literature in this area? Dr. Cao: Yeah, we have tended to do comprehensive literature reviews. When we discuss our results and compare it with existing literature, our result is quite aligned with previous literature and particularly we clearly see the racial ethnic minority have a higher prevalence of physical limitation and physical function decline. But our paper focused on the physical disability which is much more severe than the physical function. And also we also looked at another study conducted in Australia, we quite find very similar results even for cancer specific patterns of the functional disability. Dr. Shannon Westin: I guess the next question I have is was there anything that surprised you about your results? Dr. Cao: I just mentioned that what surprised me the most is that the older people are more likely to report the mobility disability, but the younger people are more likely to report self care disability. Our data don't support or explore why this happened and what's the etiology behind this. But our hypothesis is that the younger cancer survivor, younger cancer patients are more likely to receive the aggressive treatment that can play a significant role in the functional outcome. Dr. Shannon Westin: Yeah, it sounds like that's definitely an area of unmet need for more research. But I like your hypothesis. I do wonder if that's somewhat related. And I guess that leads us to our final question. What are your next steps and how can I potentially use this in practice? How can our listeners employ these findings in their practice? What do you recommend? Dr. Cao: I think our findings highlight the importance of screening for functional limitations at the baseline and throughout the cancer treatment and even the cancer survivorship. Oncology providers also should encourage patients to be physically active. And also American Society of Clinical Oncology and also American College of Sports Medicine recommend that regular exercise during the treatment can help cancer patients preserve their fitness and reduce the incidence and the severity of the cancer related disability. And also providers can provide referral to rehabilitation services and support groups for additional care. For the next step, our finding highlights the importance of developing ways to limit the long term side effects of cancer treatment both during and after treatment to preserve fixed function and prevent disability. Particularly, target intervention should in particular address special needs in vulnerable populations, including the racial ethnic minorities and those living in the rural areas to improve their quality of life during a long term survivorship. And also due to the advance in the technologies, now we want to see whether wearable sensors, wearable devices can be a novel tool to monitor their physical functions during the treatment because better monitors can lead into their better treatment and their prevention. Dr. Shannon Westin: That's great. Yeah, what a great way to end. I think that exercise clearly is key not only for preventing these issues, but also we know that it potentially can even improve response to therapy and recurrence free survival. So I think lots of reasons to be focusing on physical activity in our clinics and ensuring our patients and our cancer survivors are really participating in those types of activities. Well, Dr. Cao, it was such a pleasure. I cannot believe you are only a research fellow. I can't wait to see where your career takes you. Congratulations on this great work. Dr. Cao: Thank you. Thank you for this great opportunity to share my work and I look forward for my future work in the field. Dr. Shannon Westin: Oh, yeah. So you guys, if you're looking for somebody to come and push the boundaries of functional disability and activity, you know where to look. And again, thank you all our listeners for tuning in to another episode of JCO After Hours. Again, we were discussing, “The Prevalence and Cancer Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022.” Original research published in the JCO, April 4th, 2024. So if you're looking for more podcast offerings, check out other JCO After Hours offerings wherever you get your podcasts. Have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
In this episode, Kip Lee, VP of Innovation & Product Strategy, University Hospitals, Brian Kovach, Vice President, Cancer Institute, MetroHealth, & Joseph Rich, Senior Director, Cleveland Clinic Innovations, all share insights into the focus and future of The Cleveland Innovation District from their perspective roles.
In this episode, Kip Lee, VP of Innovation & Product Strategy, University Hospitals, Brian Kovach, Vice President, Cancer Institute, MetroHealth, & Joseph Rich, Senior Director, Cleveland Clinic Innovations, all share insights into the focus and future of The Cleveland Innovation District from their perspective roles.
In this episode, Dr. John Deeken, President at Inova Schar Cancer Institute shares insights into his background, what trends & issues in healthcare he is keeping a close eye on, what traits the most effective healthcare leaders will need to be successful in the coming years, and more.
Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and the work around a new bladder cancer therapy vaccine that represents the forefront of precision oncology.
In this episode, Dr. Wassim McHayleh, Clinical Program Director for the Breast Cancer Program, AdventHealth Cancer Institute shares insights into his background, AdventHealth's Breast Multidisciplinary (MCD) Model, how the model benefits both patients and providers, advice for other systems adopting this model, and more.
In this episode, Daniel Arnold sits down with Dianne Keen, a healthcare education and marketing specialist with over 25 years of experience in Radiology Practice Development. Dianne shares her unexpected entry into radiology and her pivotal role in promoting interventional radiology (IR) procedures. After serving as the Director of Practice Development & Strategic Initiatives at Radiology Partners, she takes on the role of Vice President of Strategy and Growth for Abbadox, a healthcare software provider specializing in Radiology workflow solutions. Dianne emphasizes the importance of understanding the clinical side, building trust with referring physicians, and advocating for women's imaging. Dianne shares her experiences in scaling radiology programs, fostering relationships with gynecologists, and ensuring breast care programs are integral to the growing Cancer Institute. Dianne also discusses her transition to Abbadox, highlighting the company's mission to improve the work lives of healthcare professionals through integrated workflow solutions. The conversation concludes with insights into the future of healthcare and radiology, emphasizing the need to adapt to technological advancements, streamline processes, and maintain a strong commitment to patient care.
As part of our Let's Finish Cancer series, Mary Renouf speaks with Dr. Melanie Goldfarb, a fellowship-trained endocrine surgeon and oncologist specializing in minimal access surgery for thyroid, parathyroid and adrenal tumors and one of the first physicians on the west coast to offer radio-frequency ablation of thyroid nodules. They discuss thyroid nodules, thyroid cancer and its different treatments.For more information and resources, visit: Providence at providence.orgProvience Saint John's Cancer Institute at saintjohnscancer.orgAnd to listen and subscribe to our Let's Finish Cancer series here:
"Finding out the patient is high-risk after they are diagnosed with cancer is too late," says Dr. Eric Brown, surgical oncologist and breast multidisciplinary team co-lead.
Today's guest is Dr. Faraz Harsini. He's a cultivated meat bioprocessing scientist at the Good Food Institute and the founder and CEO of Allied Scholars for Animal Protection – a nonprofit that supports and mentors student advocates and future vegan leaders for the abolition of cruelty to humans and nonhumans. Dr. Harsini appeared on the podcast in episode 256, in which we discussed his upbringing in Iran as a member of the LGBT community, his advocacy work on college campuses, and a myriad of social justice issues, but the conversation was so powerful, and there was so much ground we didn't get to cover, especially about his current work, that we had to have him back. So whether or not you listened to the first part of our interview with him, you definitely want to stay with us as we tackle some serious topical issues that pertain to everyone. “I guess the reason that I promote a plant-based diet and veganism full-time today is because I did my entire master's on cancer, and I worked on proteins involving cancer. And the fact that nobody ever mentioned diet at all, like I'm not talking about my research, no one, even those textbooks. And it had to come as a surprise to me when I like had to learn it by myself, and then you looked at it and you realized that every single Cancer Institute in the world says the less meat you eat, the better. Every single Cancer Institute in the world, and some even include Dairy and other types of meat, but when it comes to processed and unprocessed red meat, every single Cancer Institute in the world says the less meat you eat, the better.” - Dr. Faraz Harsini What we discuss in this episode: - The complete protein myth and why plants are such a powerful source of protein. - What happens when you cook and eat red meat? - The benefits of cultivated meat production. - The dangers posed to humans from animal experimentation. - The cruelty Dr. Harsini witnessed while visiting a dairy farm in Texas. - Dr. Harsini's thoughts on changing our food system. - The importance of speaking up as a vegan. Resources: - Dr. Harsini's website: Dr. Faraz Harsini - ASAP's website: Allied Scholars for Animal Protection - Good Food Institute: Faraz Harsini, M.Sc., Ph.D. - The Good Food Institute - Dr. Harsini's Instagram: Dr. Faraz Harsini (@dr_faraz_harsini) • Instagram photos and videos - Twitter: https://twitter.com/DrFarazHarsini - YouTube: Dr. Faraz Harsini - YouTube - Animal Activism Mentorship - https://animalactivismmentorship.com/ ★☆★ Click the link below to support the ADD SOY Act! ★☆★ https://switch4good.org/add-soy-act/ ★☆★ Share the website and get your resources here ★☆★ https://kidsandmilk.org/ ★☆★ Send us a voice message and ask a question. We want to hear from you! ★☆★ https://switch4good.org/podcast/ ★☆★ Dairy-Free Swaps Guide: Easy Anti-Inflammatory Meals, Recipes, and Tips ★☆★ https://switch4good.org/dairy-free-swaps-guide ★☆★SUPPORT SWITCH4GOOD★☆★ https://switch4good.org/support-us/ ★☆★ JOIN OUR PRIVATE FACEBOOK GROUP ★☆★ https://www.facebook.com/groups/podcastchat ★☆★ SWITCH4GOOD WEBSITE ★☆★ https://switch4good.org/ ★☆★ ONLINE STORE ★☆★ https://shop.switch4good.org/shop/ ★☆★ FOLLOW US ON INSTAGRAM ★☆★ https://www.instagram.com/Switch4Good/ ★☆★ LIKE US ON FACEBOOK ★☆★ https://www.facebook.com/Switch4Good/ ★☆★ FOLLOW US ON TWITTER ★☆★ https://mobile.twitter.com/Switch4GoodNFT ★☆★ AMAZON STORE ★☆★ https://www.amazon.com/shop/switch4good ★☆★ DOWNLOAD THE ABILLION APP ★☆★ https://app.abillion.com/users/switch4good
In this week's episode, Dr. Boris Pasche, president and CEO of Karmanos Cancer Institute, joins HealthLeaders strategy editor Jay Asser to talk about his vision for the organization and cancer care. Pasche, who took on the role in August, also offers insight on navigating workforce challenges and improving physician relations, while forecasting some of healthcare's biggest obstacles in 2024.
Lecia Bushak speaks with Ysabel Duron, founder and executive director of the Latino Cancer Institute, about health equity, especially in the Latinx community, as well as her career spanning from healthcare association leader to award-winning journalist. Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here. Music by Sixième Son.Follow us: @mmmnewsTo read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely prescribed drug venetoclax, according to a recent study published in Cancer Discovery and led by scientists from Perlmutter Cancer Center at NYU Langone Health. Today on OncTimes Talk, we interview Dr. Christina Glytsou, lead author of the study, and discuss the reasons behind leukemia cells’ resistance to venetoclax, a BH3 mimetic drug that promotes cancer cell death in individuals with AML. Dr. Glytsou holds a joint appointment as an Assistant Professor in the Department of Chemical Biology at the Ernest Mario School of Pharmacy of Rutgers University and the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School. She is a member of Cancer Metabolism & Immunology and the Cancer Pharmacology Programs, at the Cancer Institute of New Jersey. Dr. Glytsou’s laboratory aims to address fundamental questions unravelling the role of mitochondrial biology in blood malignancies’ progression and drug resistance.
Dr. Howard Edington, a surgical oncologist with AHN's Cancer Institute joins to discuss AHN opening the new Skin Cancer Center at West Penn Hospital.
Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite HamiltonHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.
Christina Curtis is a Professor of Medicine and the Director of Artificial Intelligence and Cancer Genomics at Stanford University's Cancer Institute. Among her many achievements is the conception of the “Big Bang Theory” of tumor biology. In this episode, she tells us how not being biased by assumptions of what we know has been very helpful in her research. We talk about how her background in statistical genetics has shaped her cancer research. We also discuss how the despair of not understanding is a phase that occurs in almost any research project, and we discuss the use of generative AI in the creative scientific process. For more information on Night Science, visit https://www.biomedcentral.com/collections/night-science .
In this episode, Dr. Mistry and Donna Lee are joined by Dr. Paiman Ghafoori of the Texas Cancer Institute. Dr. Ghafoori is a radiation oncologist who specializes in the use of radiation treatments for all kinds of cancer. He says the best candidates for radiation therapy are those with high-risk cancers in which surgery is the primary treatment, but additional treatments may be necessary. Although focused radiation treatments are noninvasive, complications may include urinary irritation/bladder symptoms, radiation proctitis, decreased sexual function. Fortunately, these side effects can be managed with your If you'd like to learn more about cancer treatment, give Dr. Ghafoori a call or visit him online today!Voted top Men's Health Podcast, Sex Therapy Podcast, and Prostate Cancer Podcast by FeedSpotDr. Mistry is a board-certified urologist and has been treating patients in the Austin and Greater Williamson County area since he started his private practice in 2007.We enjoy hearing from you! Email us at armormenshealth@gmail.com and we'll answer your question in an upcoming episode.Phone: (512) 238-0762Email: Armormenshealth@gmail.comWebsite: Armormenshealth.comOur Locations:Round Rock Office970 Hester's Crossing RoadSuite 101Round Rock, TX 78681South Austin Office6501 South CongressSuite 1-103Austin, TX 78745Lakeline Office12505 Hymeadow DriveSuite 2CAustin, TX 78750Dripping Springs Office170 Benney LaneSuite 202Dripping Springs, TX 78620
This episode features Dr. Mohamedtaki Tejani the Medical Director of the Gastrointestinal Oncology Program at the AdventHealth Cancer Institute in Orlando, & Dr. Amber Orman, a Radiation Oncologist and Board-Certified Lifestyle Medicine Specialist at AdventHealth Celebration. Here, they discuss a new study recently published in JAMA that shows breast, colon and pancreatic cancer rates increasing at concerning rates among America's young adults, why they believe this trend of seeing younger patients is happening, how lifestyle plays into higher rates, what can be done to decrease risk, and more.
In this JCO Article Insights episode, Emily Zabor interviews Dr. Gregory H. Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled “The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer”. Dr. Reaman introduces us to the initiative, its goals and structure, and what has already been achieved since its launch. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Emily Zabor: Welcome to this JCO Article Insights episode for the August issue of JCO. This is Emily Zabor, JCO's Biostatistics Editorial Fellow. And today I am interviewing Dr. Gregory Reaman, the Scientific Director of the Childhood Cancer Data Initiative at the National Cancer Institute, on their paper titled “The Childhood Cancer Data Initiative: Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Dr. Reaman, welcome to our podcast. Dr. Gregory Reaman: Thanks very much, Emily. Appreciate the invitation. Emily Zabor: Dr. Reaman, could you start by introducing yourself and describing your involvement in the Childhood Cancer Data Initiative? Dr. Gregory Reaman: I'm Gregory Reaman. I'm a Pediatric Oncologist. And I guess my involvement with the CCDI began shortly after the initiative was announced at the State of the Union media address in 2019, which was followed shortly thereafter by the formation of a working group by the NCI's National Cancer Advisory Board Board of Scientific Advisors. Given my role at the FDA at that time as Associate Director for Pediatric Oncology in the Oncology Center of Excellence, and the fact that I was the founding Chair of the Children's Oncology Group, I was an ex-officio member of this working group. So from very early on, I had involvement. I formally joined the NCI in November, left the FDA to assume the position as Scientific Director of CCDI. Emily Zabor: That's great. So you've really been involved from the start. I had not really been familiar with the initiative until I read this paper. And as a cancer biostatistician, I was really excited to learn about this initiative, which sounds like it will ultimately create a very valuable data resource to be used for research purposes, among other things. So I think it's a really interesting project. So for our listeners who may not be familiar, could you describe the motivation for and goals of the Childhood Cancer Data Initiative? Dr. Gregory Reaman: As I mentioned, this really is a very unique initiative, venture, if you will, on the part of the Cancer Institute and in large part driven by this fortunate infusion of funds to support childhood cancer research. And given the fact that pediatric oncology is very much a collaborative enterprise, it really does sort of follow that data sharing and using the power of data, its ability to be used by multiple investigators, irrespective of the source, aspirationally can improve outcomes for children cancer. The three primary objectives– actually, this working group that I mentioned earlier put together a white paper that had 24 specific recommendations to the NCI. But there were three foundational objectives or goals. One was to learn from every child diagnosed with cancer, irrespective of the institution where they were diagnosed to receive therapy, to develop an ecosystem that would enable the submission, aggregation of data, and harmonization in a federated system that could then be accessed and used by investigators and analyzed to ultimately improve outcomes. And then one objective, which was a little bit more specific, and that was to really focus on the opportunity to genomically classify tumors from newly diagnosed pediatric cancer patients, because this was something that obviously is much more widespread in the adult population, given the advent of targeted therapy and precision oncology and its more widespread use in medical oncology than pediatrics. And although many large academic institutions do have resources, the majority of smaller institutions do not. And when it's necessary and preferable to accurately and timely identify or diagnose a child's cancer that may actually provide information on treatment recommendations, the ability to do that and have it covered by insurance is sometimes problematic. So developing a program that would not cost patients or institutions anything and then make that data available to patients, families, and providers, as well as making it available for secondary research use, was a major goal and objective. Emily Zabor: Yeah, that sounds like such an important initiative. The Molecular Characterization Initiative, which I understand has already enrolled and characterized the genomics of 751 participants just in the first year, I think is what the paper reported? Dr. Gregory Reaman: That's correct. That was in the first year. We're now beyond the first year and we're approaching 2000 patients that have had their tumors genotyped and about 1500 results that have been returned to patients and providers. Emily Zabor: That's fantastic. So with this linkage to the clinical data, that's going to be an extremely important data source. And I understand that the participation is currently limited to members of the Children's Oncology Group, which consists of over 200 children's hospitals, universities, and cancer centers. Can you describe in more detail what information it currently provides and how this initiative is going to be advertised and implemented to ensure complete participation across all of these member sites? Because that sounds like a really big challenge. Dr. Gregory Reaman: Limiting the participation to the Children's Oncology Group initially was in no way meant to be exclusionary, but really provided an opportunity for linkage to clinical data. Since the Children's Oncology Group really represents nearly all of the pediatric cancer programs in the United States and some programs even outside the US, in Canada, and a couple of European sites, Australia and New Zealand, it was felt that given the resources that currently exist within the COG for specimen procurement, specimen submission, and then DNA and RNA extraction through the COG's Biopathology Center at the Nationwide Children's Hospital would really facilitate having the sequencing done at a single site, single institution, using a single platform. And also it provided an opportunity for some clinical data, including demographics, diagnosis, radiographic data, and treatment data that could be collected somewhat longitudinally from patients enrolled on the MCI. Looking to make this as broad as possible since the objective of the CCDI is to learn from every patient, and every patient that we're concerned about not being able to capture adequately within the Children's Oncology Group are older adolescents and young adults with cancers that are more frequently seen in the pediatric population. So we are looking at ways to work with the COG's Biopathology Center to see if we can create systems that we can actually have specimens submitted from patients seen at institutions outside of the COG and molecularly characterized the same way. And that will be important as we launch another new planned initiative called the Coordinated National Initiative for the Treatment of Rare Pediatric and Young Adult Cancers. Emily Zabor: Okay, that makes sense. So those adolescents and young adults are harder to capture since they're not being seen at those COG member institutions. Okay, well, that sounds like a big challenge to find those patients at their institutions and get them involved, but I think it's an important piece of this for sure. Dr. Gregory Reaman: I should also point out that there were opportunities for some of the larger well, for all of the NCI-designated cancer centers, the pediatric programs associated with those cancer centers, to submit genomic data on newly diagnosed patients. That was something that actually transpired early on in the history of CCDI. So those data are in the CCDI's ecosystem. Emily Zabor: Oh, that's great. So you collected the existing data. Dr. Gregory Reaman: Right. Emily Zabor: That kind of leads into my next question about aggregating data sources. With these disparate sources of pediatric cancer data, it seems like the aggregation is a lofty and important goal, but once that's complete, you're going to have this data ecosystem, which you said was one of the main goals of this initiative. I was wondering if you could tell us who will have access to this data ecosystem and what will be required for individuals to gain access. Dr. Gregory Reaman: All of CCDI was predicated on this really being a community initiative if you will, so multidisciplinary and community-based. So patients, families, advocates, clinical researchers, physician providers, basic and translational researchers, researchers in public health and epidemiology. So there will be different levels of data that will be available to specific individuals. Patient-level data will be deidentified through a system of APIs that will be used that will enable the association of clinical data to existing molecular data and outcome data that might be available in the ecosystem. Those data will be- there are many data in the ecosystem that will be open source and available to anyone who is interested. This includes data from the NCCR in the Childhood Cancer Data Catalog, which is basically a listing of some close to 300 pediatric cancer databases that are available. The patient-level data will be sort of a controlled access. So there will be a requirement for individuals, investigators who wish to access that data, to sort of be certified, if you will, utilizing NCI and NIH data sharing requirements. Emily Zabor: That makes sense. Yeah, you mentioned deidentification, but especially when we're dealing with these kinds of rare diseases, patient privacy does seem like it could be a concern. So what exactly are you doing to ensure that that is not something that gets violated through this process? Dr. Gregory Reaman: I think there's every attempt to eliminate any PPI, HPI, obviously. So, again, most of the clinical data that are being provided currently are data that's coming from the Children's Oncology Group, where for every patient enrolled or registered through the COG and enrolled on a clinical trial, there is a COG ID number that is associated and that will be available only to the NCI and the CCDI to link it to unique specimen identification numbers, which are the only numbers that will be available to any investigator. So no one will be able to make the connection from the specimen identifier to the unique patient identifier in the COG. Emily Zabor: That's great. And that way, you can really get access to all of the detailed data without concerns about privacy. Dr. Gregory Reaman: Correct. And then being able to link all of these disparate data sets will really require the identification or the development, I should say, of a participant index. So that is one of our highest priorities right now in developing a CCDI participant index so that we would be able to link the identifier or clinical data with any research data or biologic data that may be available on patients to facilitate research plans and programs. Emily Zabor: And through that process, is there also some method involved for identifying duplicated data? Because I assume some of these patients may get seen at different institutions over time, and that could be a concern that they end up in the database multiple times. Dr. Gregory Reaman: That's exactly why I think developing the participant index is so critical to, number one, link, and number two, to avoid, prevent duplication, because you're absolutely right. There may well be the same patient data in multiple data sets, which are, of course, disparate. And the only way that they're going to be really utilizable and made interoperable is by linking them to the specific patient or individual patient. Emily Zabor: Great. And do you have an idea of the timeline when that part would be complete and this data ecosystem would be available to researchers? Dr. Gregory Reaman: The ecosystem is already available to researchers. We launched several months ago the CCDI hub, which is sort of the entryway or entry point, if you will, for access to the ecosystem. We hope to actually have the participant index up and running, and it's something that we've been working on for over a year, but actually available and utilizable within the next several months. Emily Zabor: That's fantastic. We'll have to go check out the CCDI hub that's already out there then. Before we end, is there anything you'd like to share with our listeners that we haven't already discussed? Dr. Gregory Reaman: Well, I think the one program that I mentioned just briefly, the Coordinated National Initiative for Rare Pediatric and Young Adult Cancers, we see there's a real opportunity to address a major unmet need. Fortunately, all pediatric cancer is rare, but there are some cancers that are extremely rare and for which there are, in many cases, no defining standard of care, and in many cases, there are no treatment protocols because of the difficulty mounting studies with such small patient numbers. So we see this as an opportunity to actually develop a registry that will provide, hopefully, natural history data that will inform clinical trials. All of these patients will be enrolled on the Molecular Characterization Initiative. So there will be the opportunity to hopefully learn if there are specific molecular drivers of some of these cancers that could inform the use of targeted drugs in a therapeutic approach to some of these. And we're looking to do this international collaboration with colleagues in the EU as well. So that is something that we just launched a task force to develop a listing of core critical data elements to collect on patients and then developing the registries for a number of these rare cancers. Emily Zabor: That sounds like it's going to be a really valuable resource for planning and designing future clinical trials, so I'm glad to hear about that. Dr. Gregory Reaman: And we would invite anyone who's interested to find out about the CCDI, to find out more about the CCDI, which they can do through cancer.gov/ccdi. There is an opportunity for people to register for newsletters. We have a series of webinars, many of which are designed now to actually provide training on some of the resources and platforms that are available currently through the ecosystem and things that we have all planned for future developments and use. So as I said, this is a community venture and we look to expand the community in every way possible. Emily Zabor: That sounds great. So hopefully our listeners will take note of some of those resources in addition to this paper being out there, which will guide some people in the right direction to learn about this really great initiative for childhood cancer. So, Dr. Reaman, it has been a pleasure speaking with you. And thank you so much for joining me today on this episode of JCO Article Insights. Dr. Gregory Reaman: Thank you very much. It's been great to be here. Appreciate the opportunity. Emily Zabor: This concludes this episode on the article, “The Childhood Cancer Data Initiative Using the Power of Data to Learn from and Improve Outcomes for Every Child and Young Adult with Pediatric Cancer.” Thank you all for listening and please tune in for the next issue of JCO Article Insights. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Bridgeport Superintendent Carmela Levy-David has officially started in her new role this week. Learn her career story and her plans for the city's student body. ((00:00)) Oh-Oh-NO, Ozempic! A new lawsuit was filed against the makers of Ozempic and Mounjaro for claims of causing stomach paralysis in users. We spoke with Dr. Andrew Wong, Fairfield Region Medical Director of Hartford HealthCare Primary Care. He came back on to discuss the health concerns with this drug if people are solely using it as a weight loss solution. ((14:18)) There are new colon cancer screening guidelines and it's causing MAJOR confusion! Dr. Charles Cha with the Cancer Institute at St. V's explains the new recommendation and how many doctors are responding. ((30:31))
Dr. Patel is a board-certified radiologist. He has a fellowship in Body Imaging, is MQSA Certified, and is the Director of Breast Imaging. For more information about Hamilton Health Care System's imaging services, visit HamiltonHealth.com/imaging. To make an appointment for imaging at Hamilton Diagnostics Center or a mammogram at People's Cancer Institute, call 706-272-6565. To learn more about Peeples Cancer Institute, visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
Join A Cure in Sight in an interview with Dr. David Ancona, the founder of Mexico's pioneer Eye Cancer Institute. In this episode, Dr. Ancona and podcast host, Danet Peterson discuss the history of the Eye Cancer Institute in Mexico, the treatments they have available, and the effort it has taken to establish an eye cancer institute in Mexico. Their locations are in Monterry, Mexico, as well as Guatelajara, Mexico. They treat patients from all across Mexico, Central America, Southern America, and in some cases near the souther USA border. Their focus is to bring accessible, patient driven care to patients navigating eye cancer of any kind. You can find them on social media to connect and learn more at www.eyecancerinstitute.org. ANNOUNCEMENTS: 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! May 20, Raleigh, NC https://bit.ly/3KnyTwp May 21, Washington DC https://bit.ly/3ZotGIZ June 10, Minneapolis, MN coming soon! June 11, Philly, PA https://bit.ly/3U4hsUH July 8, Seattle, WA https://bit.ly/3TTgvP3 July 15, Palo Alto, CA https://bit.ly/3lRFi9D August 6, NYC/Brooklyn/Jersey area https://bit.ly/40KUtQH Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org Swing for Sight April 22, 2023 REGISTER for SWING FOR SIGHT TODAY: Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via PAYPAL OR VENMO or reach out directly to contact@acureinsight.org The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. This podcast was hosted by Danet Peterson and produced by Page Fronczek.
Join Emily Landry and Gloria Moncrief Holmsten (Moncrief Cancer Foundation) in a new episode of our WPCares podcast series as they discuss the importance of cancer prevention and screenings, early detection, and the resources available to the community through Moncrief Cancer Institute. Emily Landry is Whitley Penn's Nonprofit Industry Leader for Tax and Client Accounting & Advisory Services, and works closely with Moncrief Cancer Institute. As part of her work, Emily learns about the incredible impact nonprofit organizations are having on our communities. Through our WPCares series, Emily and others bring awareness to some of these amazing nonprofits and their resources.
https://www.GoodMorningGwinnett.com Listen to the show Monday-Thursday at 10am. Learn all about people and places around Gwinnett County. Hey if you're enjoying the show, horoscope & morning inspiration, help me keep up the good feelings by buying me a cup of coffee. Just click the link below. https://www.buymeacoffee.com/AudreyBK_________________________________________Northside Hospital is committed to expanding access to leading health care across Georgia. The health system announces the following network updates. Radiotherapy Clinics of Georgia, a partner in The US Oncology Network, in Lawrenceville is now part of Northside Hospital Cancer Institute. Northside Hospital Radiation Oncology – Duluth Highway – Lawrenceville is located at 698 Duluth Highway, Suite 100, Lawrenceville, GA 30046. Northside Hospital Radiation Oncology – Philip Blvd – Lawrenceville is located at 311 Philip Blvd., Lawrenceville, GA 30046. Both facilities opened for patients on Monday, April 3. Patients have access to the same compassionate care and nationally recognized physicians they have come to know. Both locations will offer the same providers and services. With the new partnership, patients also have access to Georgia's largest cancer network and the latest cancer research and treatments available.
This episode features Dr. Joseph Uberti, Medical Oncologist and Interim President & CEO of the Karmanos Cancer Institute, joins the podcast to talk about his background, the biggest issues he's following in healthcare going forward in 2023, what the most effective healthcare leaders need to be successful in the next 2-3 years, and more.
Evan Walgama, MD is a board-certified Otolaryngologist – Head & Neck / ENT Surgeon at the Pacific Eye, Ear & Skull Base Center at Pacific Neuroscience Institute, Santa Monica. His particular area of expertise is in the treatment of patients with benign and malignant tumors of the head and neck.Dr. Walgama is a dual-fellowship trained surgeon. He completed his Sinus and Skull Base fellowship at Stanford, followed by a Head and Neck Surgical Oncology fellowship at MD Anderson. He brings together both skillsets to treat challenging cancers of the ear, nose and throat, with a priority focus on preservation of quality of life for patients and their families. As a leader of a multidisciplinary team, Dr. Walgama addresses a wide array of benign and malignant tumors of the head and neck, including thyroid, oral cavity, throat, HPV-related, and sinus/skull base. He is a champion of multidisciplinary care and patient-centered decision making, seeing patients at award-winning Providence hospitals – Saint John's Health Center, Santa Monica, and Little Company of Mary Medical Center, Torrance, California. At Saint John's Cancer Institute, Dr. Walgama's research and academic interests include cost-effectiveness, clinical outcomes research, and clinical trials in head and neck oncology. Dr. Walgama is a member of the American Head & Neck Society, the North American Skull Base Society, and the American Academy Otolaryngology. To learn more about Dr. Walgama please visit https://www.pacificneuroscienceinstitute.org/people/evan-walgama/
Brain tumors don't get the same amount of attention as the other types of cancers. But they are still very important to talk about. My guest today is Dr. Daniel F. Kelly, a neurosurgeon and founder of Pacific Neuroscience Institute. Listen in to learn about Daniel's non-linear path to becoming a neurosurgeon. You'll also hear how the Pacific Neuroscience Institute uses keyhole surgery to reduce the amount of time patients need to stay in the hospital. What You'll Learn: We learn about Dr. Daniel F. Kelly and his background. (2:00) Daniel explains his non-linear path to becoming a neurosurgeon. (3:40) I recount some of my experiences with neurosurgeons. (5:30) Seeing a gap in specialized neuro-oncology at St. John's Cancer Institute, Daniel helped found the Pacific Neuroscience Institute. (6:00) Daniel describes the types of tumors he sees most and how that's changed over time. (8:15) We hear how Daniel got interested in pituitary tumors. (10:20) Pacific Neuroscience Institute uses a lot of collaboration to give the patient the best care (13:05) We hear how patients' pathways may differ when treated by Daniel. (14:26) Not every brain tumor patient requires surgery. (17:20) The essence of keyhole surgery is to sneak in and sneak out. (18:36) Daniel explains how surgery has evolved throughout his career. (21:30) Not every neurosurgeon specializes in keyhole surgery. (22:00) The COVID-19 pandemic reduced the amount of time neuro-patients stayed in hospitals post surgery. (24:30) Neuro-patients are incredibly brave and resilient. (27:16) Daniel explains how he collaborates with different specialists. (30:00) There are some exciting advances happening in neurosurgery. (32:00) Pacific Neuroscience Institute is looking for a cure for Glioblastoma. (35:05) Psychedelic assisted therapy is currently having a renaissance. (36:30) Daniel describes various studies on psychedelic assisted therapy. (39:14) We discuss the Netflix show 'How to Change Your Mind'. (44:00) Ideas worth sharing: "Not everyone who has a brain tumor needs surgery." - Dr. Daniel F. Kelly "The essence of Keyhole Surgery is to sneak in and sneak out with minimum collateral damage." - Dr. Daniel F. Kelly "Managing patient expectations is important for all areas of oncology." - Dr. Rosalyn Morrell "All of my patients teach me so much. We think we're teaching them and educating them -- but a lot of times it's the other way around." - Dr. Rosalyn Morrell Resources: Dr. June Wiley: USC Pacific Neuroscience Institute: Website Dr. Daniel F. Kelly: Email
On the latest episode of Territory Talk, co-hosts Doug Plagens and Jameson Olive discuss the latest road trip and upcoming homestand for the Florida Panthers. Plus, Dr. Michael Zinner, who serves as the Chief Executive Officer and Executive Medical Director of Baptist Health's Miami Cancer Institute, joins the show to talk about Saturday's “Hockey Fights Cancer Night” and more.Highlights of the episode include:Looking back at Florida's four-game road trip. (1:45)Brandon Montour steps into the spotlight. (6:30)Dr. Zinner of Baptist Health Miami's Cancer Institute joins the show! (19:15)Doug and Jameson are off to a rough start in the prediction game. (29:00)
This episode features Dr. Mohamedtaki Tejani, Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Here, he explains three clinical trials underway at AdventHealth to evaluate the effectiveness and impact of different types of ctDNA testing for colorectal cancer patients. Circulating tumor DNA (ctDNA) is a sequencing technology that can detect very small amounts of tumor DNA in the body's circulatory system via a blood draw and specialized assay.
1. 'RHOA' Alum Cynthia Bailey & Husband Split (TMZ) 2. 'Glee' Controversies Explored in Discovery+ Docuseries From Ample Entertainment (Deadline) 3. Anne Hathaway Says Her 'Devil Wears Prada Look' at NYFW Was an 'Accident': 'It Was Kind of Nuts' (PEOPLE) 4. Heidi Klum and daughter Leni, 18, slammed for 'weird' and 'disturbing' lingerie ad (NY Post) 5. 'RHOBH' star Lisa Rinna slammed by Cancer Institute over finale comments (Page Six) The Toast with Jackie (@JackieOshry) and Claudia Oshry (@girlwithnojob) NLOG Tickets: https://www.girlwithnojob.com/tour Merch: https://www.shopmorningtoast.com/ The Toast Patreon: https://www.patreon.com/themorningtoast Girl With No Job by Claudia Oshry: https://www.girlwithnojob.com/book
Videos: Dr. Ryan Cole: Covid Vaccine Side Effects Are Like A Nuclear Bomb New Rule: F*** tha Casting Police | Real Time with Bill Maher (HBO) Renters In America Are Running Out Of Options Consuming green vegetables, supplements suppresses inflammatory bowel disease Sichuan University in China and from Cedars Sinai Medical Center, August 17, 2022 The dietary supplement chlorophyllin alleviates inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, according to researchers from the Center for Diabetes and Metabolism Research at Sichuan University in China and from Cedars Sinai Medical Center in Los Angeles. In addition, chlorophyllin significantly reduces mortality related to IBD, weight loss, diarrhea and hidden blood in the stool, intestinal epithelial damage and infiltration of inflammatory cells. The findings are published ahead of print in the American Journal of Physiology-Gastrointestinal and Liver Physiology, and the study has been chosen as an APS select article for August. Current therapeutics for IBD include medications that suppress the immune system (immunosuppressants) and surgery. However, long-term use of immunosuppressive treatments could result in severe adverse effects, including opportunistic infections and even organ failure. In this study, researchers found taking an oral chlorophyllin supplement—a compound derived from the green pigment found in plants—reduced colitis and abnormalities in the intestinal epithelia of mice. Also, consumption of green vegetables and chlorophyllin may be helpful for IBD recovery, in part through alleviation of inflammation and autolysosomal flux (a process that uses lysosome to degrade and remove toxic molecules and organelles). Green pigment found in these foods and supplements can initiate a feeding signaling to modulate autophagy in the cells, which suppresses IBD symptoms. (next) Coriander is a potent weapon against antibiotic resistant bacteria University of Beira Interior (Portugal) August 10, 2022 The problem of antibiotic resistant bacteria has been deemed a public health crisis, with the Centers for Disease Control and Prevention (CDC) reporting that invasive MRSA – or methicillin-resistant S. aureus – infections affect 80,000 people globally a year, and claim over 11,000 lives. But, what the CDC will never tell you is how coriander can potentially save lives. Researchers in Portugal now say that that the oil from coriander – a common kitchen spice – is quite toxic to a wide range of harmful bacteria, leading to hopes that it may be enlisted in the fight against MRSA and other pathogens. The scientific research about coriander is promising Researchers at University of Beira Interior used flow cytometry to study the effects of coriander oil on 12 different disease-causing types of bacteria, including E. coli, Salmonella, B. cereus and MRSA. In the study, published in Journal of Medical Microbiology, the oil significantly inhibited bacterial growth – especially that of MRSA and E. coli. (next) Tumour blood supply stopped in its tracks by modified natural compound University of New South Wales (Australia), August 10, 2022 Researchers have discovered how the modified natural compound dextran-catechin disrupts formation of blood vessels that fuel growth in the childhood cancer neuroblastoma. Researchers have discovered how a modified natural compound disrupts angiogenesis, the formation of blood vessel networks, in neuroblastoma tumours, stopping them laying down the vital supply lines that fuel cancer growth and spread. Dextran catechin is a sugar based conjugated form of catechin commonly found in green tea, red wine, dark chocolate and apple peels. Lead author Dr Orazio Vittorio of Children's Cancer Institute found that the natural polyphenol catechin slows tumour growth in the laboratory but breaks down too quickly in the body to be effective. (next) Researchers discover how DDT exposure contributes to Alzheimer's disease risk Florida International University and Rutgers University, August 17, 2022 A new study led by researchers from Florida International University and Rutgers reveals a mechanism linking the pesticide DDT to Alzheimer's disease. Published in Environmental Health Perspectives, the study shows how the persistent environmental pollutant DDT causes increased amounts of toxic amyloid beta, which form the characteristic amyloid plaques found in the brains of those with Alzheimer's disease. According to Jason Richardson, professor at FIU's Robert Stempel College of Public Health & Social Work and corresponding author, the study further demonstrates that DDT is an environmental risk factor for Alzheimer's disease.”The vast majority of research on the disease has been on genetics—and genetics are very important—but the genes that actually cause the disease are very rare,” Richardson says. “Environmental risk factors like exposure to DDT are modifiable. So, if we understand how DDT affects the brain, then perhaps we could target those mechanisms and help the people who have been highly exposed.” The study focused on sodium channels, which the nervous system uses to communicate between brain cells (neurons), as the potential mechanism. DDT causes these channels to remain open, leading to increased firing of neurons and increased release of amyloid-beta peptides. In the study, researchers demonstrate that if neurons are treated with tetrodotoxin, a compound that blocks sodium channels in the brain, the increased production of the amyloid precursor protein and toxic amyloid-beta species is prevented. “This finding could potentially provide a roadmap to future therapies for people highly exposed to DDT,” Richardson says. (next) Study shows how food preservatives may disrupt human hormones and promote obesity Cedars-Sinai Medicine Institute, August 9, 2022 Can chemicals that are added to breakfast cereals and other everyday products make you obese? Growing evidence from animal experiments suggests the answer may be “yes.” But confirming these findings in humans has faced formidable obstacles – until now. A new study published in Nature Communications details how Cedars-Sinai investigators developed a novel platform and protocol for testing the effects of chemicals known as endocrine disruptors on humans. The three chemicals tested in this study are abundant in modern life. Butylhydroxytoluene (BHT) is an antioxidant commonly added to breakfast cereals and other foods to protect nutrients and keep fats from turning rancid; perfluorooctanoic acid (PFOA) is a polymer found in some cookware, carpeting and other products; and tributyltin (TBT) is a compound in paints that can make its way into water and accumulate in seafood. The investigators used hormone-producing tissues grown from human stem cells to demonstrate how chronic exposure to these chemicals can interfere with signals sent from the digestive system to the brain that let people know when they are “full” during meals. When this signaling system breaks down, people often may continue eating, causing them to gain weight. (next) Standing desks can improve well-being, reduce stress among office workers University of Leicester (UK), August 17 2022 Standing desks can improve workers' performance as well as cut their time sitting by an hour each day, according to new research. Study authors add that getting up from an office chair also boosts well-being and energy levels, while reducing stress. “High levels of sitting time are associated with several health related outcomes and premature mortality, with high levels of workplace sitting associated with low vigor and job performance and high levels of presenteeism.” Presenteeism is the practice of being present at one's place of work for more hours than is required, especially as a manifestation of insecurity about one's job. Sedentary lifestyles increase the risk of chronic conditions including cardiovascular disease, type 2 diabetes, depression, anxiety, and cancer.
© 2020-2025 Ivy Podcast Discovery LLC
